Hello Avatar! Welcome back for another week of biotech analysis. Today we are going to dig into the topic of the dirty term sheet. Currently both the public and private biotech markets are at a nexus. Public markets have clearly turned negative. However, valuations (particularly on the private side) are still in the process of readjusting. Managemen…
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.